Bone Non Current Liabilities Total from 2010 to 2025

BBLGW Stock  USD 89.77  20.52  29.63%   
Bone Biologics Non Current Liabilities Total yearly trend continues to be fairly stable with very little volatility. Non Current Liabilities Total will likely drop to 759.63 in 2025. During the period from 2010 to 2025, Bone Biologics Non Current Liabilities Total regression line of quarterly data had mean square error of 15.9 T and geometric mean of 0.00. View All Fundamentals
 
Non Current Liabilities Total  
First Reported
2014-12-31
Previous Quarter
0.0
Current Value
0.0
Quarterly Volatility
3.5 M
 
Yuan Drop
 
Covid
Check Bone Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bone Biologics' main balance sheet or income statement drivers, such as Other Operating Expenses of 11.4 M, Ebitda of 453.2 K or Total Operating Expenses of 11.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.39. Bone financial statements analysis is a perfect complement when working with Bone Biologics Valuation or Volatility modules.
  
Check out the analysis of Bone Biologics Correlation against competitors.

Latest Bone Biologics' Non Current Liabilities Total Growth Pattern

Below is the plot of the Non Current Liabilities Total of Bone Biologics Corp over the last few years. It is Bone Biologics' Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bone Biologics' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Total10 Years Trend
Slightly volatile
   Non Current Liabilities Total   
       Timeline  

Bone Non Current Liabilities Total Regression Statistics

Arithmetic Mean3,872,839
Geometric Mean0.00
Coefficient Of Variation103.69
Mean Deviation3,034,002
Median3,645,194
Standard Deviation4,015,754
Sample Variance16.1T
Range12.2M
R-Value(0.28)
Mean Square Error15.9T
R-Squared0.08
Significance0.30
Slope(235,298)
Total Sum of Squares241.9T

Bone Non Current Liabilities Total History

2025 759.63
2024 799.61
2022 888.46
202199.9 K
202012.2 M
201911.3 M
2018null

About Bone Biologics Financial Statements

Bone Biologics investors use historical fundamental indicators, such as Bone Biologics' Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Bone Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Liabilities Total 799.61  759.63 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Bone Stock Analysis

When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.